Physician profile
Jodella Locklear
NPI 1578565164
$1,259.54
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $778 · 2022: $324 · 2023: $114 · 2024: $43.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $157.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $221.73 | 2021-2023 | |
| Novo Nordisk INC | $187.95 | 2021-2023 | Saxenda, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $137.99 | 2021-2023 | Farxiga |
| Lilly USA, LLC | $124.32 | 2021-2023 | Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.86 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $81.35 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.68 | 2021-2023 | Jardiance |
| Pfizer INC. | $64.61 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $42.59 | 2021 | |
| Amarin Pharma, INC. | $35.84 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.29 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.43 | 2021-2024 | Trintellix |
| Abbott Laboratories | $23.74 | 2022 | |
| Merck Sharp & Dohme LLC | $23.22 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $18.18 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $15.12 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.59 | 2021 | |
| Glaxosmithkline, LLC. | $14.03 | 2021 | |
| Nevro Corp. | $13.02 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodella Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.